Jean M. Francis, MD

Assistant Professor, Medicine

Jean Francis
(617) 638-7330
650 Albany St Evans Biomed Research Ctr

Biography

2009-current: Medical Director of Kidney Transplantation Program, BUSM, Boston, MA
2015-current: Medical Director of Pancreas Transplantation, Brigham and Women’s Hospital, Boston, MA
2015-current: Co-director of Thrombotic Microangiopathy Program, BUSM, Boston, MA

Research Interests:

Thrombotic microangiopathy (TMA) is a rare but very serious condition. It is characterized by widespread microthrombi formation in multiple organs (in its severe and disseminated form) or localized microthrombi in the kidney (in its limited form). TMA is usually characterized by thrombocytopenia, microangiopathic hemolytic anemia (MAHA), and multiple organ injury and dysfunction.

Early detection and accurate diagnosis are essential to implement appropriate therapies, and improve patients’ prognosis and survival. Delay in diagnosis could result in late implementation of appropriate therapies, and this could result in permanent and irreversible organ damage. Left untreated TMA is associated with very high level of morbidity and mortality. TMA presentation could be highly variable making the diagnosis even more difficult. Once the diagnosis of TMA is established, defining the underlying cause is even more challenging due to frequent overlap between the common causes of TMA.

We have a unique multidisciplinary approach to the management of this very rare disease. A TMA team was established at Boston University Medical Center with the primary objective of improving patients care and outcome. Our Team works in close collaboration with the ARC on Thrombosis.

A primary goal of the team is to provide excellent patient care. The TMA team is multidisciplinary involving: nephrologists, hematologists, the director of apheresis, pediatric hematologist and pharmacist. They are always available to manage any patient with suspected TMA. Special protocols and algorithm have been created by the team to help guiding the provider in making an accurate diagnosis of any TMA case.

Another goal of the TMA team is educational. We are actively spreading awareness of this rare disease between our providers at BMC, and also regionally and nationally by organizing lectures and seminars as well as mini-symposia.

A third goal of the TMA team is to advance basic and clinical research related to TMA. We are active in clinical trials addressing the efficacy of newer agents for the treatment of complement mediated HUS a special form of TMA. Our scientists are also trying to understand some underlying pathological mechanisms that could be contributing to TMA.

A link to our team is available at:
http://www.bu.edu/ctsi/support-for-research/bumc-thrombotic-microangiopathy-collaborative-butmac/butmac/

Education

  • Lebanese University, MD
  • Lebanese University, BS

Publications

  • Published on 7/15/2017

    Gordon CE, Chitalia VC, Sloan JM, Salant DJ, Coleman DL, Quillen K, Ravid K, Francis JM. Thrombotic Microangiopathy: A Multidisciplinary Team Approach. Am J Kidney Dis. 2017 Nov; 70(5):715-721. PMID: 28720207.

    Read at: PubMed
  • Published on 5/21/2017

    Tapan U, Lee SY, Weinberg J, Kolachalama VB, Francis J, Charlot M, Hartshorn K, Chitalia V. Racial differences in colorectal cancer survival at a safety net hospital. Cancer Epidemiol. 2017 Aug; 49:30-37. PMID: 28538169.

    Read at: PubMed
  • Published on 3/1/2017

    Reddy YN, Siedlecki AM, Francis JM. Breaking down the complement system: a review and update on novel therapies. Curr Opin Nephrol Hypertens. 2017 Mar; 26(2):123-128. PMID: 27977428.

    Read at: PubMed
  • Published on 11/17/2016

    Gordon CE, Vantzelfde S, Francis JM. Acetazolamide in Lithium-Induced Nephrogenic Diabetes Insipidus. N Engl J Med. 2016 11 17; 375(20):2008-2009. PMID: 27959610.

    Read at: PubMed
  • Published on 11/1/2016

    Shashar M, Siwak J, Tapan U, Lee SY, Meyer RD, Parrack P, Tan J, Khatami F, Francis J, Zhao Q, Hartshorn K, Kolachalama VB, Rahimi N, Chitalia V. c-Cbl mediates the degradation of tumorigenic nuclear ß-catenin contributing to the heterogeneity in Wnt activity in colorectal tumors. Oncotarget. 2016 11 01; 7(44):71136-71150. PMID: 27661103.

    Read at: PubMed
  • Published on 7/19/2016

    Toth-Manikowski SM, Francis JM, Gautam A, Gordon CE. Outcomes of bisphosphonate therapy in kidney transplant recipients: a systematic review and meta-analysis. Clin Transplant. 2016 Sep; 30(9):1090-6. PMID: 27327448.

    Read at: PubMed
  • Published on 4/13/2016

    Francis JM, Beck LH, Salant DJ. Membranous Nephropathy: A Journey From Bench to Bedside. Am J Kidney Dis. 2016 Jul; 68(1):138-47. PMID: 27085376.

    Read at: PubMed
  • Published on 3/24/2016

    Ding Y, Francis J, Kalish J, Deshpande A, Quillen K. Recurrent focal segmental glomerulosclerosis apparently resistant to plasmapheresis improves after surgical repair of arteriovenous fistula aneurysms. Clin Kidney J. 2016 Jun; 9(3):408-10. PMID: 27274825.

    Read at: PubMed
  • Published on 11/3/2015

    Al-Rabadi L, Francis JM, Henderson J, Ghai S. Proliferative glomerulonephritis with monoclonal immunoglobulin in renal allografts. Clin Kidney J. 2015 Dec; 8(6):722-8. PMID: 26613031.

    Read at: PubMed
  • Published on 5/27/2015

    Shivanna S, Kolandaivelu K, Shashar M, Belghasim M, Al-Rabadi L, Balcells M, Zhang A, Weinberg J, Francis J, Pollastri MP, Edelman ER, Sherr DH, Chitalia VC. The Aryl Hydrocarbon Receptor is a Critical Regulator of Tissue Factor Stability and an Antithrombotic Target in Uremia. J Am Soc Nephrol. 2016 Jan; 27(1):189-201. PMID: 26019318.

    Read at: PubMed

View 16 more publications: View full profile at BUMC

View all profiles